These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9269481)

  • 1. In vitro dissolution profile comparison and IVIVR. Carbamazepine case.
    Sathe P; Tsong Y; Shah VP
    Adv Exp Med Biol; 1997; 423():31-42. PubMed ID: 9269481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro dissolution profile comparison: statistics and analysis, model dependent approach.
    Sathe PM; Tsong Y; Shah VP
    Pharm Res; 1996 Dec; 13(12):1799-803. PubMed ID: 8987074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The bioinequivalence of carbamazepine tablets with a history of clinical failures.
    Meyer MC; Straughn AB; Jarvi EJ; Wood GC; Pelsor FR; Shah VP
    Pharm Res; 1992 Dec; 9(12):1612-6. PubMed ID: 1488405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discriminatory dissolution method for quality control measurements of carbamazepine immediate release tablets based on in vitro--in vivo investigations.
    Xu C; Zou M; Wang Y; Liu Y; Yan J; Wu Y; Cheng G
    Drug Dev Ind Pharm; 2012 Jun; 38(6):679-88. PubMed ID: 21988132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Dissolution Profiles From Process Parameters, Formulation, and Spectroscopic Measurements.
    Zhao Y; Li W; Shi Z; Drennen JK; Anderson CA
    J Pharm Sci; 2019 Jun; 108(6):2119-2127. PubMed ID: 30742835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impairment of the in vitro release of carbamazepine from tablets.
    Uzunović A; Vranić E; Hadzidedić S
    Bosn J Basic Med Sci; 2010 Aug; 10(3):234-8. PubMed ID: 20846131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surfactant effects upon dissolution patterns of carbamazepine immediate release tablet.
    Lee H; Park SA; Sah H
    Arch Pharm Res; 2005 Jan; 28(1):120-6. PubMed ID: 15742820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation.
    Kovacević I; Parojcić J; Homsek I; Tubić-Grozdanis M; Langguth P
    Mol Pharm; 2009; 6(1):40-7. PubMed ID: 19248231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a biphasic in vitro dissolution test for estimating the bioavailability of carbamazepine polymorphic forms.
    Deng J; Staufenbiel S; Bodmeier R
    Eur J Pharm Sci; 2017 Jul; 105():64-70. PubMed ID: 28487146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biopharmaceutical characterization of carbamazepine immediate release tablets. In vitro-in vivo comparison.
    Homsek I; Parojcic J; Cvetkovic N; Popadic D; Djuric Z
    Arzneimittelforschung; 2007; 57(8):511-6. PubMed ID: 17915636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and in vitro evaluation of multiparticulate sustained release carbamazepine formulation.
    Tomuţă I; Leucuţa SE
    Acta Pol Pharm; 2012; 69(5):951-64. PubMed ID: 23061293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance comparison of a co-crystal of carbamazepine with marketed product.
    Hickey MB; Peterson ML; Scoppettuolo LA; Morrisette SL; Vetter A; Guzmán H; Remenar JF; Zhang Z; Tawa MD; Haley S; Zaworotko MJ; Almarsson O
    Eur J Pharm Biopharm; 2007 Aug; 67(1):112-9. PubMed ID: 17292592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vitro-In Vivo Correlations of Carbamazepine Nanodispersions for Application in Formulation Development.
    Warnken Z; Puppolo M; Hughey J; Duarte I; Jansen-Varnum S
    J Pharm Sci; 2018 Jan; 107(1):453-465. PubMed ID: 29045883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of carbamazepine 200 mg tablets.
    Kibwage IO; Nguyo M
    East Afr Med J; 1993 Aug; 70(8):512-4. PubMed ID: 8261973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbamazepine level-A in vivo-in vitro correlation (IVIVC): a scaled convolution based predictive approach.
    Veng-Pedersen P; Gobburu JV; Meyer MC; Straughn AB
    Biopharm Drug Dispos; 2000 Jan; 21(1):1-6. PubMed ID: 11038432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo evaluation of novel immediate release carbamazepine tablets: complexation with hydroxypropyl-β-cyclodextrin in the presence of HPMC.
    Kou W; Cai C; Xu S; Wang H; Liu J; Yang D; Zhang T
    Int J Pharm; 2011 May; 409(1-2):75-80. PubMed ID: 21371541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory Perspectives on Strength-Dependent Dissolution Profiles and Biowaiver Approaches for Immediate Release (IR) Oral Tablets in New Drug Applications.
    Suarez-Sharp S; Delvadia PR; Dorantes A; Duan J; Externbrink A; Gao Z; Ghosh T; Miksinski SP; Seo P
    AAPS J; 2016 May; 18(3):578-88. PubMed ID: 26928450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical Considerations Concerning Dissimilar Regulatory Requirements for Dissolution Similarity Assessment. The Example of Immediate-Release Dosage Forms.
    Jasińska-Stroschein M; Kurczewska U; Orszulak-Michalak D
    J Pharm Sci; 2017 May; 106(5):1275-1284. PubMed ID: 28088455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.